Search research articles
Contact Us
Filters
Showing results (121-130 of 234) with videos related to
Page
of 24
Sort By:
Arthritis Research & Therapy
|
July 25, 2006
Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis
Karim Raza, Dagmar Scheel-Toellner, Chi-Yeung Lee, et al.
Rheumatology (Oxford, England)
|
October 14, 2017
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Lupus Science & Medicine
|
December 5, 2019
Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
Peter Izmirly, Jill Buyon, H Michael Belmont, et al.
Journal of Autoimmunity
|
December 8, 2023
Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: The Michigan Lupus Epidemiology & Surveillance (MILES) Program
Emily C Somers, Jaclyn M Goodrich, Lu Wang, et al.
Rheumatology (Oxford, England)
|
June 13, 2018
Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Rheumatology (Oxford, England)
|
October 14, 2017
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Rheumatology (Oxford, England)
|
April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Daniel J Wallace, Caroline Gordon, Vibeke Strand, et al.
Arthritis and Rheumatism
|
December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Eclinicalmedicine
|
October 21, 2024
Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study
Melanie Sloan, James A Bourgeois, Guy Leschziner, et al.
Arthritis and Rheumatism
|
December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
Chee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Page
of 24
Search research articles
Search
Showing results (121-130 of 234) with videos related to
Sort By:
Page
of 24
Arthritis Research & Therapy
|
July 25, 2006
Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis
Karim Raza, Dagmar Scheel-Toellner, Chi-Yeung Lee, et al.
Rheumatology (Oxford, England)
|
October 14, 2017
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Lupus Science & Medicine
|
December 5, 2019
Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
Peter Izmirly, Jill Buyon, H Michael Belmont, et al.
Journal of Autoimmunity
|
December 8, 2023
Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: The Michigan Lupus Epidemiology & Surveillance (MILES) Program
Emily C Somers, Jaclyn M Goodrich, Lu Wang, et al.
Rheumatology (Oxford, England)
|
June 13, 2018
Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Rheumatology (Oxford, England)
|
October 14, 2017
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Rheumatology (Oxford, England)
|
April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Daniel J Wallace, Caroline Gordon, Vibeke Strand, et al.
Arthritis and Rheumatism
|
December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Eclinicalmedicine
|
October 21, 2024
Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study
Melanie Sloan, James A Bourgeois, Guy Leschziner, et al.
Arthritis and Rheumatism
|
December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
Chee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Page
of 24